Juan Manuel Sambade

Juan Manuel Sambade

Auto-generated profile, based on publicly available information

Juan Manuel Sambade

Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2025 in PLOS ONE
Verified
Journal Article
Open access
Ariel BardachAriel Bardach
Ariel Bardach
MBMabel Berrueta
Mabel Berrueta
ACAgustín Ciapponi
Agustín Ciapponi
JSJuan M. Sambade
Juan M. Sambade
NCNoelia Castellana
Noelia Castellana
PBPierre Buekens
Pierre Buekens
Background: Lassa fever (LF) is an acute viral hemorrhagic illness endemic in West Africa, representing significant public health challenges, particularly for pregnant persons and children who experience higher morbidity and mortality. Although several vaccine candidates are being developed, no LF vaccine has been licensed yet. Methods: We conducted a living systematic review (LSR) of the literature to evaluate the safety, efficacy, effectiveness, and immunogenicity of LF vaccines. We performed biweekly searches in major biomedical databases, trial registries, preprint servers, and other sources. Eligible studies included preclinical studies, clinical trials, and observational studies published from January 2014 to April 2025. Reviewer pairs screened studies extracted data (REDCap), and assessed risk of bias independently. Data synthesis involved random-effects pairwise and proportion meta-analyses (R software), with GRADE assessment of evidence certainty. PROSPERO registries: (CRD42024514513; CRD42024516754). Results: Searches retrieved 1423 records, including 51 studies, 2 clinical trials in adults involving 88 vaccinated persons, and 49 preclinical studies of 30 vaccine candidates. Trials evaluated Recombinant Measles-Vectored (MV-LASV) and Recombinant Vesicular Stomatitis Virus-based (rVSVΔG-LASV-GPC) LF vaccine candidates. No published clinical trials were found to evaluate LF vaccines in special populations such as pregnant persons, infants, children, or adolescents. Although injection site reactogenicity was reported, no vaccine-related serious adverse events (SAEs) were reported in study participants. Immunogenicity was robust in adults, with vaccines achieving around 95% seroconversion at 30 days. Preclinical data evaluated nine different platforms. Findings are disseminated via an interactive online dashboard ( https://safeinpregnancy.org/living-systematic-review-lassa/ ). Conclusion: Currently, two LF vaccine candidates that have advanced to clinical trials exhibit high immunogenicity, but the safety profile in healthy adults is still limited. Clinical evidence in pregnant persons, infants, children, and adolescents is absent. Vaccine platforms of interest have been identified in preclinical studies, providing information on those that could advance to clinical studies.

14 February 2025 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
JBJamile Ballivian
Jamile Ballivian
EPEdward P.K. Parker
Edward P.K. Parker
MBMabel Berrueta
Mabel Berrueta
ACAgustin Ciapponi
Agustin Ciapponi
FAFernando Argento
Fernando Argento
PBPierre Buekens
Pierre Buekens
Background: The COVID-19 pandemic induced the rapid deployment of novel vaccines with pregnant persons identified as an at-risk population due to their increased risk of severe outcomes. Limited data on the immunogenicity of COVID-19 vaccines in pregnant persons were available at the time of implementation. To address this data gap, we developed a living systematic review summarizing emerging evidence on vaccine immunogenicity in pregnancy. Methods: Following Cochrane, World Health Organization, and Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines, we included studies on COVID-19 vaccines during pregnancy. We carried out comprehensive biweekly literature searches from March 2022 to October 2023, covering multiple databases. Study selection, data extraction and risk of bias assessment were conducted by pairs of authors independently. Immunogenicity outcomes, primarily post-vaccination neutralizing or binding antibody concentrations, were analyzed descriptively. Post-vaccination antibody ratios in pregnant versus nonpregnant individuals were calculated for the subset of studies that included nonpregnant comparators. Results: By October 2023, our review encompassed 62 studies predominantly analyzing maternal sera (87%), with limited investigation regarding cord, neonatal and infant sera. Most studies investigated mRNA vaccines (97%) and focused on primary vaccination (82%), with some investigating booster doses (15%). Immunogenicity end points included spike-specific IgG (84%) and neutralizing antibodies (24%), with limited data on T-cell responses (3%). Antibodies were detectable after primary vaccination in most pregnant individuals, with similar or modestly attenuated concentrations compared to nonpregnant individuals (ratios > 0.7 for 5/6 estimates of spike-specific IgG), albeit with modest differences in antibody quality and kinetics. Long-term antibody-waning trajectories were similar between pregnant and nonpregnant individuals for up to 8 months after vaccination. Conclusions: mRNA COVID-19 vaccines induce a robust antibody response during pregnancy comparable (or modestly attenuated) relative to nonpregnant individuals. Immunogenicity data on non-mRNA vaccines are notably underrepresented in the existing literature.

21 November 2025 in Nicotine & Tobacco Research
Verified
Journal Article
Closed access
Ariel BardachAriel Bardach
Ariel Bardach
ASAswathy Sreedevi
Aswathy Sreedevi
JSJuan M Sambade
Juan M Sambade
ENEmiliano Navarro
Emiliano Navarro
GMG K Mini
G K Mini
APAndrés Pichón-Riviere
Andrés Pichón-Riviere
Introduction: Tobacco use is a major global health risk, causing over eight million deaths annually. The World Health Organization Framework Convention on Tobacco Control requires member countries to adopt a raft of comprehensive policy measures, including taxation. In India, 28% of adults consume tobacco, with a high prevalence of both combustible and smokeless forms, contributing to a substantial health burden. To inform tobacco tax policy in India, we estimated the potential impact of taxation on lowering the prevalence of use and the associated health and economic burden. Methods: We employed a Markov probabilistic microsimulation to simulate the impact of increasing tobacco taxes on tobacco-related diseases, healthcare costs, productivity losses, and quality of life over a lifetime horizon. Results: Combustible tobacco use in India is responsible for ~922 000 deaths and 8.9 million disease events annually. Smokeless tobacco (SLT) contributes to 165 000 deaths and 400 000 disease events. The economic burden of direct and indirect costs is substantial: INR 3.56 trillion for combustible tobacco and INR 358 billion for SLT. Increasing tobacco taxes by 50% could avert 1.8 million deaths (~9.8% of tobacco-attributable deaths over 10 years), 66.8 million healthy life-years lost, and provide economic benefits exceeding INR 11.9 trillion over 10 years. Conclusions: Tobacco use remains a major health and economic burden in India. Both combustible and SLT cause high mortality and morbidity. Taxation emerges as a potentially effective tool to reduce deaths, life years lost, and economic losses, with economic benefits reported exclusive of additional tax revenue. Implications: Our study adds to the existing body of evidence by providing a detailed, India-specific analysis that distinguishes between the health and economic impacts of combustible versus smokeless tobacco. We estimated the disease burden and economic costs attributable to each form of tobacco and projected the potential benefits of increased tobacco taxation. Our findings show that a 50% increase in tobacco taxes could prevent 1.8 million deaths and save nearly INR 11.9 trillion over 10 years. This study uniquely quantifies the differential impacts of various tobacco products and offers robust evidence to support targeted tobacco control policies.

16 October 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
Ariel BardachAriel Bardach
Ariel Bardach
ACAgustín Ciapponi
Agustín Ciapponi
DCDaniel Comandé
Daniel Comandé
ADAyelén Silvana D’ALmeida
Ayelén Silvana D’ALmeida
VSValentina Stacco
Valentina Stacco
GBGabriela Brenta
Gabriela Brenta
Background: Evidence on clinical and subclinical hypothyroidism in Latin America and the Caribbean (LAC) is dispersed, heterogeneous, and often non-representative, limiting its use for regional burden estimation and decision making. We synthesized epidemiological, quality-of-life, economic, and equity-related evidence to assess what can and cannot be inferred from the current evidence base.Methods: We searched 12 bibliographic databases and grey literature sources for studies published between Jan 1, 2014, and Dec 5, 2024, with no language restrictions. Eligible designs included observational studies, economic evaluations, and surveillance reports from LAC. Paired reviewers screened records, extracted data, and assessed risk of bias using NIH tools and CiCERO. We conducted random-effects meta-analyses of proportions. The protocol was registered in PROSPERO (CRD420251033806).Findings: We included 145 studies from 19 LAC countries, predominantly from upper-middle-income settings. Most samples were non-probabilistic and focused on newborns or adults. Pooled prevalence was 3·6% for clinical/overt hypothyroidism (95% CI 2·7–4·6; I² 95·6%) and 9·1% for subclinical hypothyroidism (95% CI 7·2–11·4; I² 98·4%), both increasing with age. Annual incidence was 0·51% for overt hypothyroidism (95% CI 0·38–0·68) and 1·03% for subclinical hypothyroidism (95% CI 0·84–1·26). Among studies reporting sex-disaggregated data, women represented 66% of clinical/overt cases and 55% of subclinical cases. Risk-of-bias assessments rated studies included in the main meta-analyses as fair or good, but between-study heterogeneity was extreme and most samples were non-probabilistic, limiting interpretation as precise regional burden estimates. Seven studies reported health-related quality-of-life decrements, particularly in mental and social domains. Economic evidence was sparse, intervention-specific, and insufficient to quantify the regional burden.Interpretation: Hypothyroidism is commonly reported in LAC, but extreme heterogeneity and non-probabilistic sampling preclude precise regional burden estimates. Priorities include harmonised diagnostic thresholds, population-based surveillance, sex-disaggregated reporting, and multicountry economic studies.

15 October 2026 in JMIR Research Protocols
Verified
Journal Article
Open access
AMAgustina Mazzoni
Agustina Mazzoni
Ariel BardachAriel Bardach
Ariel Bardach
MBMabel Berrueta
Mabel Berrueta
ACAgustin Ciapponi
Agustin Ciapponi
KKKaren Klein
Karen Klein
PBPierre Buekens
Pierre Buekens
Background: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract disease in infants, with the highest burden in the first 6 months of life. Maternal immunization with the bivalent (RSV-A and RSV-B) prefusion F (RSVPreF) protein subunit vaccine (ABRYSVO) is a recently recommended strategy for preventing RSV-related outcomes in infants. First licensed for use in pregnancy in 2023, the RSVPreF vaccine demonstrated efficacy in a single pivotal randomized trial (Maternal Immunization Study for Safety and Efficacy; MATISSE); postlicensure real-world evidence on vaccine effectiveness across settings, seasons, and subgroups and on antibody durability and transplacental transfer remains limited and has not been synthesized in a continuously updated framework, motivating this review. Objective: This living systematic review and meta-analysis will synthesize emerging postlicensure data on the efficacy, effectiveness, and immunogenicity of the RSVPreF vaccine in real-world settings. Methods: We will conduct, in real time, a living systematic review and meta-analysis following Cochrane methods and PRISMA-P (Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols) guidance, including randomized clinical trials and postlicensure real-world studies (eg, cohort, case-control, test-negative, and quasi-experimental studies). Primary objectives are evaluation of vaccine efficacy and effectiveness in preventing RSV-specific and all-cause respiratory disease and immunogenicity in infants and pregnant individuals. Vaccine effectiveness outcomes include RSV laboratory-confirmed infection, RSV acute respiratory illness, RSV lower respiratory tract disease, RSV hospitalization, RSV complications, all-cause lower respiratory tract disease and hospitalization, and antibiotic use in infants with RSV infection. Immunogenicity outcomes include maternal neutralizing antibody titers, maternal-infant transfer ratios, infant titers over time, and RSV viral load. We will search MEDLINE, Embase, the Cochrane Library, LILACS, Science Citation Index Expanded, Chinese biomedical and citation databases, clinical trial registries from January 2023 onward with no language restrictions, updating at least monthly. Two investigators will independently select studies, extract data, and assess risk of bias. Adjusted estimates will be standardized to vaccine efficacy and effectiveness. Certainty will be graded using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system. Results: This living systematic review was funded in June 2025. Searches began in January 2023 and will continue with surveillance updates at least monthly until April 2028. As of January 2026, 837 records were screened, 105 (12.5%) were assessed in full text, and 12 (1.4%) met the inclusion criteria, of which 10 (1.2%) contributed extractable data. Data collection and analysis are ongoing and displayed on an interactive dashboard. Findings will be disseminated through peer-reviewed publications, conferences, and a real-time dashboard, with the first effectiveness estimates available in July 2026. Conclusions: This living systematic review and meta-analysis will provide a continuously updated synthesis of real-world evidence on maternal RSVPreF vaccination to inform clinical and policy decisions.